Cleary Gottlieb은 기업거래, 독점규제 및 공정거래, 정부감독, 소송 및 중재 등의 분야에서 세계적인 생명공학 및 제약회사들을 상대로 활발한 자문활동을 하고 있습니다.

저희는 또한 자본시장에서 이러한 회사들의 자본조달을 해주는 금융기관들에게도 자문을 제공합니다.

저희 변호사들은 세계 각국에 위치한 12개 사무소에서 고객들이 인수·합병, 합작 기타 그들의 사업목적을 이루기 위한 기업거래를 완수할 수 있도록 각국의 규제에 관한 자문업무에 매진하고 있습니다.

Practice highlights include:

• Regular EC law counsel to Merck & Co. on a cutting-edge issues, including in precedent-setting European Court of Justice win regarding the interpretation of the World Trade Organization’s Agreement on Trade Related Aspects of Intellectual Property Rights and in antitrust challenges by generic companies.
• Antitrust counsel to GlaxoSmithKline in connection with numerous transactions, including its recent $15 billion bid to acquire Pfizer’s consumer health care business.
• Counsel to Boehringer Ingelheim in precedent-setting European Court of Justice win regarding the scope of trademark owners’ rights in relation to parallel importers that repackage pharmaceutical products.
• Regular counsel to Medtronic on a range of matters, including in its $3.9 billion Kyphon acquisition.
• Counsel to TPG, Blackstone, Goldman Sachs and KKR in $10.9 billion Biomet acquisition—one of the largest LBOs of all time.
• Antitrust counsel to Merck & Co. in its collaboration with GTx to advance research and development of selective androgen receptor modulators (SARM).
• Regular global counsel to 3M, including in the sale of its global pharmaceuticals business to three buyers.
• Counsel to GlaxoSmithKline in many litigation matters, including a class action litigation in U.S. federal court relating to allegations of patent misuse in connection with Augmentin, GSK’s drugs for treating HIV/AIDS; a U.S. class action challenging GSK’s efforts to restrict illegal export and price-fixing of its products; the simultaneous resolution of a number of pending actions related to Wellbutrin XL; as well as on antitrust issues arising from the settlement of a patent litigation involving Paxil.
• Counsel to GlaxoSmithKline and its U.S. subsidiary SmithKline Beecham in the $1.65 billion acquisition of Reliant Pharmaceuticals, as well as to GSK in its acquisitions of Domantis Limited, Praecis Pharmaceuticals, CNS, ID Biomedical Corporation and Corixa.
• Counsel to Lundbeck in connection with the distribution of pharmaceutical products in Europe.